Contact: Dennis J. Curtin, Chief Financial Officer
Telephone: 1-800-544-4624, ext. 320

E-Z-EM, INC., Reports Results for Third Quarter 2002

Westbury, New York; April 15, 2002 E-Z-EM, E-Z-EM, Inc., (AMEX: EZM.A and EZM.B) today
announced results for the third fiscal quarter ended March 2, 2002. The Company reported 
net earnings of $1,157,000, $.12 and $.11 per share on a basic and diluted basis, 
respectively, on net sales of $30,646,000. In the third quarter of fiscal 2001, the Company 
announced net earnings of $106,000, $.01 per share, on net sales of $27,809,000. 

For the first nine months of fiscal 2002, the Company reported a net loss of $122,000, 
($.01) per share, on net sales of $88,916,000. In the comparable period last year, the 
Company had net earnings of $2,809,000, $.28 per share, on net sales of $82,200,000. 

Commenting on the Company's results, Anthony A. Lombardo, E-Z-EM's President and CEO, said, 
"We are pleased with the growth in sales across the Company. Sales in the third fiscal quarter, 
which ended March 2, 2002, were significantly improved over prior year third quarter results."

"Sales in our Diagnostic segment increased over last year's third quarter due to contributions 
from our contract manufacturing segment and continued growth in the area of CT contrast products.
Operating profit for the quarter increased $1,128,000 over last year's quarter, despite the 
continued investment the Company has been making in the area of virtual colonoscopy as well as 
CT contrast and injector systems. The Diagnostic segment continues to lead in the development 
of clinical systems for supporting the emerging markets in virtual colonoscopy. We recently 
received FDA clearance for our PROTOCO2L(TM) carbon dioxide insufflator, and released the 
InnerviewGI(TM) 3D software diagnostic platform in conjunction with our strategic partner, 
Vital Images Inc. 

"Our AngioDynamics subsidiary continued its strong growth, with sales for the quarter up 
44% from last year, and year-to-date sales increasing 32%. This increase in sales came from 
growth in vascular access products, angiographic catheters and stent/angioplasty products. 
Our decision to focus on the interventional radiology area, and our continued investment in 
sales force support and new product line extensions and introductions, are resulting in 
double-digit growth in this rapidly expanding market. Despite these continued investments, 
operating profit for AngioDynamics improved $633,000 over last year's third quarter and 
$1,848,000 over the first nine months of fiscal 2001." 

Results for the year-to-date were impacted by restructuring costs of $1,492,000 related to the 
decision to close the Company's Japanese manufacturing facility in December 2001 and focus on 
the growing sales of contrast systems manufactured in the U.S. and imported into the large 
Japanese market. The restructuring charge impacted earnings for the year by $.16 per share. 
In last year's nine-month period, several factors combined to have a favorable effect on net 
earnings of $418,000, or $.04 per basic share. These factors included the favorable reversal 
of a tax valuation allowance of $1,344,000, offset by the pre-tax write-down of $450,000 for 
acquired patent rights to an oral MRI contrast agent, and a pre-tax loss of $872,000 from 
the sale of a manufacturing facility in the Republic of Ireland owned by the Company's 
AngioDynamics subsidiary. 

The Company's cash and short-term marketable securities at March 2, 2002, were $19.3 million, 
up $1.2 million from fiscal year end 2001. Net book value per common share outstanding was 
$8.17 at March 2, 2002. The Company's balance sheet and financial position remain strong. 

Commenting on the overall results, Mr. Lombardo said, "The Company continues to invest in 
positioning itself in the high growth area of CT systems, including virtual colonoscopy, 
contrast agents and injector systems. Our focus on interventional radiology as a best 
practice company is demonstrating what a concerted investment strategy can produce in terms 
of positioning AngioDynamics as a leading supplier, clinical partner and innovator in this 
rapidly growing marketplace." 

About E-Z-EM, Inc. 

E-Z-EM, the world's largest manufacturer of contrast agents for gastrointestinal radiology, 
has developed the only CT injector on the market that can help detect contrast extravasation, 
the new EmpowerCT with patented EDA technology. The Company has also recently introduced a 
complete tool kit for virtual colonoscopy (also referred to as CT colonography, or CTC), 
an innovative technology that could lead to a substantial increase in the number of patients 
being screened for colorectal cancer. Virtual colonoscopy visualizes the gastrointestinal 
tract using advanced CT imaging and 3D computer reconstruction of that data. The Company's 
product line consists of the InnerviewGI(TM) 3D imaging workstation; LoSo Prep(TM) and 
NutraPrep(TM) patient-friendly colon preparation products and nutritional meal kits; a 
tagging agent trade-named Tagitol(TM) to help practitioners distinguish pathology from 
colonic residue; and the PROTOCO2L(TM) carbon dioxide colon insufflation system.

E-Z-EM's wholly owned subsidiary, AngioDynamics, manufactures a wide range of products, 
including angiographic, vascular access, thrombolytic, angioplasty, stents, as well as 
abdominal infection drainage products. AngioDynamics' focus is on diagnostic and 
therapeutic products for interventional radiology and other areas of minimally invasive 
surgery. Enteric Products, Inc., another subsidiary, develops, manufactures and markets 
tests for detection of the ulcer- and cancer-causing bacterium Helicobacter pylori. For 
additional information, please contact Frank Kerrigon at 1-800-544-4624, ext. 325, 
(E-mail: fkerrigon@ezem.com) or visit our corporate web site at www.ezem.com. 

The statements made in this document contain certain forward-looking statements that involve 
a number of risks and uncertainties. Words such as "expects", "intends", "anticipates", 
"plans", "believes", "seeks", "estimates," or variations of such words and similar 
expressions, are intended to identify such forward-looking statements. Investors are 
cautioned that actual events or results may differ from the Company's expectations. In 
addition to the matters described above, the ability of the Company to develop its products, 
future actions by the FDA or other regulatory agencies, results of pending or future clinical 
trials, overall economic conditions, general market conditions, foreign currency exchange 
rate fluctuations, the effects on pricing from Group Purchasing Organizations, competition, 
including alternative procedures which continue to replace traditional fluoroscopic 
procedures, as well as the risk factors listed from time to time in the SEC filings of 
E-Z-EM, Inc., including but not limited to its Form 10-Q for the quarter ended March 2, 2002,
as well as its Annual Report on Form 10-K for the year ended June 2, 2001, may affect the 
actual results achieved by the Company.

End